Clearside Biomedical to Present at the 17th Annual Needham Healthcare Conference

ALPHARETTA, Ga., March 21, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ: CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced today that its Chief Executive Officer and President, Daniel H. White, will present at the 17th Annual Needham Healthcare Conference on Tuesday, March 27, 2018 at 1:30 p.m. ET at The Westin Grand Central Hotel in New York, NY.

A live webcast of the presentation can be accessed on the company’s website at www.clearsidebio.com under the “Events & Presentations” tab in the “Investor Relations” section. Following the conference, the presentation webcast will be archived on the website for approximately 30 days.

About Clearside

Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a late-stage clinical ophthalmic biopharmaceutical company that envisions a world without blindness.  Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and preclinical product candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This has the potential to offer meaningful treatment benefit to patients suffering from sight-threatening diseases like uveitis, retinal vein occlusion, diabetic macular edema and wet age-related macular degeneration. To learn more about how Clearside is changing ophthalmology, please visit us at www.clearsidebio.com.

Contacts:

Stephen Kilmer
Investor Relations
(678) 270-3631
[email protected]

Charles Deignan
Chief Financial Officer
(678) 270-4005
[email protected]

You May Also Be Interested In

• PetroChina Achieves a Strong Start for "the 15th Five-Year Plan" Interim Operating Results for the First Half of 2026 Hit New Record Highs
• Bayer Announces Phase III REVEAL Study with Investigational PET Radiotracer Iodine 124 Evuzamitide Presented as Late-Breaker at ESC 2026
• Veteran-Founded Heating Firm Marks 15 Years Across Hampshire